Previous Article | Next Article 
Infection and Immunity, May 1999, p. 2090-2095, Vol. 67, No. 5
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Epitope Mapping of Monoclonal Antibodies against
Bordetella pertussis Adenylate Cyclase Toxin
S.-J.
Lee,1
M. C.
Gray,2
L.
Guo,2,
P.
Sebo,3 and
E. L.
Hewlett1,2,*
Departments of
Pharmacology1 and
Medicine,2 University of Virginia,
Charlottesville, Virginia, and Institute for Microbiology,
Czech Academy of Sciences, Prague, Czech Republic3
Received 28 October 1998/Returned for modification 16 December
1998/Accepted 26 January 1999
 |
ABSTRACT |
Adenylate cyclase (AC) toxin from Bordetella pertussis
is a 177-kDa repeats-in-toxin (RTX) family protein that consists of four principal domains; the catalytic domain, the hydrophobic domain,
the glycine/aspartate-rich repeat domain, and the secretion signal
domain. Epitope mapping of 12 monoclonal antibodies (MAbs) directed
against AC toxin was conducted to identify regions important for the
functional activities of this toxin. A previously developed panel of
in-frame deletion mutants of AC toxin was used to localize MAb-specific
epitopes on the toxin. The epitopes of these 12 MAbs were located
throughout the toxin molecule, recognizing all major domains. Two MAbs
recognized a single epitope on the distal portion of the catalytic
domain, two reacted with the C-terminal 217 amino acids, one bound to
the hydrophobic domain, and one bound to either the hydrophobic domain
or the functionally unidentified region adjacent to it. The remaining
six MAbs recognized the glycine/aspartate-rich repeat region. To
localize these six MAbs, different peptides derived from the repeat
region were constructed. Two of the six MAbs appeared to react with the
repetitive motif and exhibited cross-reactivity with Escherichia
coli hemolysin. The remaining four MAbs appeared to interact with
unique epitopes within the repeat region. To evaluate the roles of
these epitopes on toxin function, each MAb was screened for its effect
on intoxication (cyclic AMP accumulation) and hemolytic activity. The
two MAbs recognizing the distal portion of the catalytic domain blocked intoxication of Jurkat cells by AC toxin but had no effect on hemolysis. On the other hand, a MAb directed against a portion of the
repeat region caused partial inhibition of AC toxin-induced hemolysis
without affecting intoxication. In addition, the MAb recognizing either
the hydrophobic domain or the unidentified region adjacent to it
inhibited both intoxication and hemolytic activity of AC toxin. These
findings extend our understanding of the regions necessary for the
complex events required for the biological activities of AC toxin and
provide a set of reagents for further study of this novel virulence factor.
 |
INTRODUCTION |
Bordetella pertussis, a
gram-negative bacterium which causes whooping cough, produces several
essential virulence factors (37, 38). One of these is
adenylate cyclase (AC) toxin, which invades eukaryotic cells,
catalyzing the conversion of ATP into cyclic AMP (cAMP) after
activation by host calmodulin (4, 13, 22, 24, 25). The
consequences of this intoxication include inhibition of host immune
cell function (9, 30) and macrophage death through apoptosis
(29). AC toxin has also been demonstrated to elicit
K+ efflux from sheep erythrocytes in a process that is
thought to represent an antecedent event to osmotic lysis of sheep
erythrocytes (16). Very little is known, however, about the
mechanism by which AC toxin penetrates membranes.
AC toxin is synthesized and secreted as a single polypeptide of 177 kDa
and consists of four principal domains (13, 28). (i) The
N-terminal catalytic domain (amino acids 1 to 400) is activated by
calmodulin to convert endogenous ATP into cAMP (4). (ii) The
hydrophobic region (amino acids 500 to 700) is hypothesized to include
as many as four membrane-spanning
-helices and may contribute to
channel formation in membranes (3, 35). (iii) The repeat
region (amino acids 1000 to 1600), which contains 38 copies of the
glycine/aspartate-rich motif GGXGXDXLX, is involved in Ca2+
binding (27, 33). Such a tandem arrangement of
glycine/aspartate-rich repeats characterizes the RTX (repeats in toxin)
family (10, 39). The secondary structure of the repetitive
motif is predicted to be similar to that of the alkaline protease of
Pseudomonas aeruginosa (2). One of the proposed
functions of this repeat region is targeting AC toxin to the
cytoplasmic membrane of target cells; however, no specific cell surface
receptor has been identified (15, 28). (iv) The C-terminal
domain (amino acids 1600 to 1706) contains the secretion signal and
seems to play a structural role, since a deletion mutant lacking the
secretion signal has no biological activity (14, 28).
Over the past 10 years, we have prepared a number of hybridoma cells
secreting monoclonal antibodies (MAb) directed against AC toxin, two of
which have been described previously. MAb 9D4 and 1H6 were used for
Western blotting in the initial purification of AC toxin and
identification of the holotoxin molecule (26). In addition,
MAb 1H6 was used to characterize the conformational change, which
occurs after Ca2+ is bound to AC toxin (27). To
help identify functionally important regions of AC toxin, we have
localized epitopes of a set of MAbs by using a panel of in-frame
deletion mutants of AC toxin. In addition, each MAb has been evaluated
for its effect on AC toxin-induced hemolysis and intracellular cAMP
accumulation, to begin to elucidate the relationships of the structure
and function of AC toxin.
 |
MATERIALS AND METHODS |
Bacterial strains, plasmids, and recombinant DNA techniques.
Escherichia coli XL1-Blue (Stratagene) was used to
overexpress wild-type toxin and the deletion mutant proteins. E. coli M15/pREP4 (Qiagen) (Nals Strs
Rifs lac ara gal mtl F
recA+ uvr+) was used for the
production of small peptides of the repeat region which were poorly
expressed in XL1-Blue. Plasmid pREP4 contains the lacI gene
to give the host bacterium 10-fold-higher levels of lac
repressor. All the plasmids in this study were transformed into
E. coli competent cells by the calcium chloride cold-shock method. Deletion constructs (see Fig. 1) were described previously (28, 34). To enhance the resolution of mapping, small
peptides of the repeat region in Fig. 3 (left) were constructed. An
insert introducing six histidine residues at the N terminus (pR1) was obtained by subcloning the SacI-SmaI fragments of
pT7ACT1 into the SacI-SmaI sites of pQE30
(Qiagen). Plasmid pT7CACT1 was derived from pCACT3 by placing
cyaC under control of both lacZp and
T7p promoters and was used for preparation of AC toxin in
earlier studies (5, 16). To make pR2, an insert was prepared
by digesting pT7ACT1 with SphI, creating blunt-ended
fragments with S1 nuclease (Boehringer Mannheim), and further digesting
the linearized pT7ACT1 with SacI. This insert was subcloned
into the SacI-SmaI sites of pQE30. Plasmid pR3
was constructed by taking a DNA fragment encoding amino acids 1156 to
1319 and amplifying it by PCR with oligonucleotide primers 5-CAT
GCG AGC TCT GGG GCC-3 and 5-TCC CCC GGG CCC CCC GTA-3.
The amplified fragment was double digested with SacI
and SmaI and ligated into the same sites of the pQE30 vector. Plasmid pR4 contains the DNA insert encoding amino acids 1320 to 1489. This DNA fragment was amplified by PCR with oligonucleotides 5-CGC CCA TCC GGG GGG CTG GGC GAC-3 and 5-GTC GAC CCG
GGC CGC TGA-3 and cloned into the BamHI and
SmaI sites of pQE30. To construct pR5, pT7CACT1 was digested
with ClaI and BlpI and the ends were filled in
with Klenow polymerase (New England BioLabs) and then ligated into the
pGEX2T (Pharmacia) SmaI site. The direction of the inserted
fragment was confirmed by restriction mapping.
Production of MAbs against AC toxin.
Two groups of MAbs, (i)
9D4, 7C7, 2F5, 1H6, 2B12, and 4H2 and (ii) 3D1, 5D1, 10A8, 6E1, 10A8,
and 2A12, were derived from separate fusions. Hybridoma cells in the
first group were prepared from the fusion of myeloma cells and
splenocytes of BALB/c mice immunized by standard procedures
(8) with AC toxin purified by sucrose gradient
centrifugation (26). Screening for hybridoma cells producing
MAbs directed against AC toxin was based upon immunoprecipitation of
the enzymatic activity of AC toxin from a preparation comparable to
that used for immunization. At a later date, when AC toxin had been
purified and characterized, the second panel of antibodies was derived
from BALB/c mice immunized with a palmitoylated synthetic peptide of
the acylation region, surrounding Lys983, and boosted with holotoxin.
By using purified holotoxin (1 µg/well) as the antigen, the culture
supernatants containing MAbs directed against AC toxin were identified
by indirect ELISA. From each hybridoma, ascites was prepared as
previously described (26) and all the MAbs were purified
from the ascites by affinity chromatography on protein A-Sepharose. The
titer of each MAb was defined as the dilution of purified MAb eliciting
an optical density of greater than 1.00 in an indirect ELISA. The
isotype of each MAb was determined with an Isostrip MAb isotyping kit
(Boehringer Mannheim) as specified by the manufacturer.
Preparation of AC toxin and mutant proteins.
E. coli
XL1-Blue, transformed with the plasmid encoding wild-type AC toxin or
its derivative, was grown in 2× YT (1.6% Bacto Tryptone, 1% Bacto
Yeast, 85 mM NaCl) (Difco) to optical density at 600 nm of 0.2, induced
with 1 mM IPTG (Boehringer Mannheim), and grown for another 4 h at
37°C. The bacteria were sonicated and extracted in 8 M urea-50 mM
Tris-HCl (pH 8.0)-150 mM NaCl. Soluble proteins were separated from
cell debris by centrifugation. Holotoxin and mutant proteins were
further purified by affinity chromatography on calmodulin-Sepharose 4B
(Pharmacia) as described previously (27, 34). Urea extract
of the
AC deletion mutant was used in this study because this
deletion mutant cannot be purified by calmodulin-Sepharose. His-tagged
proteins pR1, pR2, pR3, and pR4, were purified by
Ni+-agarose affinity chromatography (Qiagen) as specified
by the manufacturer. The GST fusion protein pR5 was purified by
glutathione-Sepharose affinity chromatography (Pharmacia) as specified
by the manufacturer. E. coli hemolysin was prepared as
described previously (11).
Immunoblotting.
Prepared proteins were subjected to sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (10%
polyacrylamide) by the method of Laemmli (29a). After
SDS-polyacrylamide gel electrophoresis, the proteins were transferred
to Immobilon filters (PVDF; Millipore), blocked with 1% bovine serum
albumin dissolved in TSB (50 mM Tris [pH 7.5], 200 mM NaCl), and
incubated for 2 h at room temperature with MAb at 1:1,000
dilution. The membrane was washed three times with TSB and incubated
with peroxidase-conjugated anti-mouse immunoglobulin G for 1 h at
room temperature. The membrane was washed three times with TSB and
exposed to 0.5 mg of chloronaphthol per ml in TSB-0.01% hydrogen
peroxide for 5 min at room temperature to allow visualization.
Proteins pR1 through pR5 were dotted onto a nitrocellulose membrane by
using a minifold apparatus (Schleicher & Schuell). This membrane was
allowed to air dry and tested for MAb reactivity as described above.
Intoxication by AC toxin.
Intoxication was determined by
measuring intracellular cAMP accumulation in Jurkat cells exposed to AC
toxin. For determination of the inhibitory effect of antibodies, toxin
(2.5 µg/ml) was incubated with each MAb (10 µg/ml) at room
temperature for 5 min. Jurkat cells (106/ml) in Hanks
balanced salt solution were added to the mixture, which was then
incubated at 37°C for 30 min. At the end of the incubation, the cells
were centrifuged for 7 min at 2,200 × g, and medium
was removed by aspiration. The cells were resuspended in 1 ml of 0.1 N
HCl for extraction of intracellular cAMP. After centrifugation, the
supernatants were carefully transferred to tubes for cAMP measurement
by automated radioimmunoassay (7, 16).
Determination of hemolytic activity.
Hemolytic activity was
determined by measuring the amount of hemoglobin released into the
culture medium. AC toxin (5 µg/ml) was incubated with each MAb (20 µg/ml) for 5 min at room temperature. Washed sheep erythrocytes at
5 × 108/ml in Hanks balanced salt solution were
added, and the mixture was incubated for 5 h at 37°C. Nonlysed
sheep erythrocytes were pelleted by centrifugation at 2,200 × g for 5 min, and hemoglobin released into the supernate was
quantitated by measurement of the optical density at 541 nm. Background
hemoglobin release was subtracted from experimental values.
 |
RESULTS |
Screening MAbs against AC toxin.
Hybridomas that were found to
secrete MAbs against AC toxin were used to induce ascites fluid in
BALB/c mice, and the antibodies were purified on a protein A affinity
column. The isotypes of all MAbs used in this study were determined by
immunodiffusion and are listed in Table
1. In addition, ELISA titers for each purified MAb were measured as described in Materials and Methods and
are also listed in Table 1.
Epitope mapping of anti-AC toxin MAbs.
The epitope recognized
by each anti-AC toxin MAb was determined by the pattern of
immunoreactivity against a set of in-frame deletion mutants of AC
toxin. The toxin derivatives used in this study, which are
schematically presented in Fig. 1, were
constructed so that some or all of each major domain of the toxin was
deleted (28, 34). These deletion mutant proteins were
separated on an SDS-polyacrylamide gel, transferred to PVDF, and tested
for their reactivity with each MAb by Western blotting. The results of
this type of evaluation for all the MAbs tested are summarized in Table
2. As an example, the reactivity of each
MAb with
R, the deletion mutant lacking a major part of the repeat
region (amino acids 1009 to 1489), is shown in Fig.
2. Of the 12 MAbs, 5, i.e., 6E1, 9D4,
4H2, 2B12, and 2F5, did not react with this deletion mutant, suggesting
that the deleted segment contains the epitopes of these MAbs. One
possible explanation for the prevalence of MAbs to this region is that
some or all are directed against 1 of the 38 glycine/aspartate-rich
repeat motifs. To test this hypothesis, peptides of the repeat region
were constructed and are shown schematically in Fig.
3 (left). Interestingly, these five MAbs
reveal several different immunoblotting patterns, as shown in Fig. 3
(right). MAbs 9D4 and 2F5 seem to recognize repetitive epitopes in the
repeat region because they are reactive to all derivatives of the
protein containing amino acids 1156 to 1489, including pR3 and pR4
segments, which do not overlap. Of 12 MAbs tested for cross-reactivity
with E. coli hemolysin, only 9D4 and 2F5 showed
cross-reactivity (Fig. 4). MAb 9D4 was
previously reported to react with E. coli hemolysin (HlyA)
(11) and Neisseria meningitidis FrpA
(36), which have a glycine/aspartate-rich repeat domain characteristic of RTX-related molecules. On the other hand, MAb 6E1
reacts with all peptides except pR4 (amino acids 1320 to 1489), suggesting that it binds to a unique epitope at the proximal portion of
the repeat region, namely, amino acids 1156 to 1319. Interestingly, MAb
7C7, which reacts with
R (containing amino acids 1 to 1008 and 1490 to 1706) and
HR3 (amino acids 1 to 384 and 1590 to 1706), also
recognized pR1 (amino acids 1156 to 1489), pR4 (amino acids 1320 to
1489), and pR5 (amino acids 813 to 1627) as shown in Table 2 and Fig. 3
(right). This suggests that the epitope of 7C7 may be a repetitive
motif located throughout amino acids 1320 to 1627. The last two MAbs,
2B12 and 4H2, react with pR5 (amino acids 813 to 1627),
H (amino
acids 1 to 384, and 829 to 1706) and
Cla (amino acids 1 to 827 and
888 to 1706) but not with
HR1 (lacking amino acids 385 to 1006).
Therefore, they appear to recognize the region between amino acids 888 and 1006. However, 2B12 and 4H2 do not recognize
R, which includes
amino acid 888 to 1006. These results suggest that the epitopes of both
2B12 and 4H2 are localized at amino acids 888 to 1006 but require
additional amino acids distal to residue 1006 for their conformation.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic diagrams of AC toxin-derivative deletion
mutants. The lines correspond to the deleted portion of full-length AC
toxin. The designation of each deletion mutant is given on the left,
and the deleted segment is indicated on the right.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoblot analysis of the R deletion mutant protein
by using each MAb. R protein from AC toxin was purified from a
calmodulin affinity column, subjected to electrophoresis on a 10%
polyacrylamide gel, transferred to a PVDF membrane, and immunoblotted.
Molecular mass standards are indicated by arrows.
|
|


View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Immuno-dot-blot analysis with MAbs 9D4, 2F5, 6E1, 7C7,
4H2, and 2B12, using different peptides of repeat region. (Left)
Schematic representation of the peptides derived from the repeat
region. (Right) The peptides of the repeat region were dotted onto
nitrocellulose membrane and probed with each MAb as described in
Materials and Methods.
|
|

View larger version (7K):
[in this window]
[in a new window]
|
FIG. 4.
Western immunoblot analysis of the reactivity of each
MAb with E. coli hemolysin. Approximately 5 µg of E. coli hemolysin was subjected to SDS-polyacrylamide gel
electrophoresis, transferred to a PVDF membrane, and incubated as
described in Materials and Methods.
|
|
MAbs 3D1 and 5D1 recognize
AC (amino acids 373 to 1706) and
C1308
(amino acids 1 to 399) but do not react with AC toxin deletion mutant
C1322 (amino acids 1 to 384). This would suggest that MAbs 3D1 and
5D1 recognize an epitope located between amino acids 385 and 399. A
synthetic peptide consisting of amino acids 385 to 399 was synthesized;
however, it was unable to elicit binding of 3D1 or 5D1 (data not
shown). We interpret these data to indicate either that the epitope is
not linear and these MAbs cannot bind to the synthetic peptide or that
the epitope requires additional amino acids proximal to residue 385 for
its conformation. Since we cannot rule out either of these
possibilities and since both of these MAbs bind to
AC (amino acids
373 to 1706), we have provisionally assigned the epitope for these MAbs
as amino acids 373 to 399.
MAbs 10A1 and 2A12 do not react with deletion mutant
H, lacking the
entire hydrophobic domain and functionally unidentified regions
adjacent to the hydrophobic domain (Table 2). In addition, the deletion
mutant
Bgl (deletion between amino acids 624 and 780) has lost the
epitope of MAb 10A1 but
Cla (deletion between amino acids 828 and
887) has not. This result indicates that the epitope of 10A1 is likely
to be located between amino acids 624 and 780. In contrast, MAb 2A12,
which does not react with
H (amino acids 1 to 384 and 829 to 1706)
or
C1308 (amino acids 1 to 398), recognized
Bgl, suggesting that
its epitope is localized at either end of the 624-to-780 deletion
(between amino acids 399 and 623 or 781 and 828).
There are two MAbs, 10A8 and 1H6, which recognize the C-terminal
secretion signal region. These MAbs react with both
HR3, which
consists of both N-terminal amino acids 1 to 384 and C-terminal amino
acids 1590 to 1706, and
C75, lacking the C-terminal 75 amino acids.
However, they do not bind
HR4, consisting of both the catalytic
domain (amino acids 1 to 384) and C-terminal amino acids 1632 to 1706, or
C217, lacking the C-terminal 217 amino acids, suggesting that its
epitope is located within amino acids 1590 to 1631.
Inhibition of biological activities of AC toxin.
To address
the predicted functional role of each domain or epitope, we screened
each MAb for its ability to affect the enzymatic activity required to
convert ATP to cAMP in a cell-free system, the toxin activity required
to enter cells, and the hemolytic activity. None of the MAbs had an
effect on the enzymatic activity of AC toxin required to convert ATP to
cAMP in a cell-free system (data not shown). The results of inhibition
of intoxication and hemolytic activities are summarized in Table
3. When 3D1 or 5D1 was allowed to bind to
AC toxin prior to its addition to cells, AC toxin-induced cAMP
accumulation was inhibited by more than 95% in Jurkat cells. On the
other hand, neither of these MAbs had any effect on the hemolytic
activity of AC toxin, implying that they did not impair the binding of
the toxin to cells as required for hemolysis. These results suggest
that the N-terminal amino acids 373 to 399 recognized by 3D1 and 5D1
are important for delivery of the catalytic domain into the cell
interior.
MAb 2A12, which binds to amino acids 399 to 623 or 781 to 828, partially blocked cAMP accumulation in Jurkat cells but also interfered
with the lysis of sheep erythrocytes. This suggests that this MAb
inhibits the binding of AC toxin to cells or affects some other event
common to these activities.
MAb 6E1 strongly delayed the onset of the lysis of sheep erythrocytes
but did not impair AC toxin-induced cAMP accumulation (Table 3). These
results suggest that MAb 6E1 may block one of the steps required only
for hemolysis.
 |
DISCUSSION |
AC toxin is an essential virulence factor for B. pertussis (37, 38). This toxin is immunogenic and has
been shown to elicit antibody responses in patients infected with
B. pertussis and recipients of whole-cell pertussis vaccine
(1, 6, 12). These observations led to the hypothesis that
this immune response to AC toxin could be protective; indeed, this has
been confirmed in a series of studies. AC holotoxin or a fragment which
contains only adenylate cyclase activity has been shown to function as a protective antigen when used in immunizations (17, 18,
19). Subsequently, however, Betsou et al. (5)
demonstrated that posttranslational acylation of AC toxin is required
for protective activity. In addition, they observed that native AC
toxin from B. pertussis is a more potent protective antigen
than is recombinant AC toxin expressed in E. coli. This
difference could be because native AC toxin is expressed with a
different acylation pattern from recombinant AC toxin (20,
21). Furthermore, Betsou et al. localized the protective epitope
of the toxin, demonstrating that the repeat region of AC toxin is
necessary for protection and that sera from immunized infants
recognized this region (6). This result is in contrast to
previous results by Guiso et al. (19) indicating that the
catalytic domain is sufficient for protective activity. The
insufficient characterization of AC toxin as a protective antigen at
the time when acellular vaccines were formulated precluded its being
considered as a component in those products (23). The
studies described above, however, establish a theoretical basis for
inclusion of AC toxin in future acellular vaccines.
Prior attempts to map MAbs to AC toxin were limited since a panel of
deletion mutants was not available. Therefore, mapping of those MAbs
had to be done by using cross-reactivity with mutants of the related
RTX toxins (38a). For example, MAb 9D4 reacts with E. coli hemolysin (11) and N. meningitidis FrpA
(36), suggesting that it binds an epitope in the
glycine/aspartate-rich repeat region which is the common structural
feature among RTX toxins.
In this report, we present the epitope mapping of 12 MAbs against AC
toxin by using immunoblotting of toxin deletion mutants as summarized
in Fig. 5. In addition, each MAb was
screened for the ability to inhibit biological activities of AC toxin
(Table 3). All these results were used to evaluate the structures of epitopes in parallel with functions previously assigned to major domains. For example, MAbs 3D1 and 5D1 block intoxication but have no
effects on the hemolytic activity. Amino acids 373 to 399 comprise the
region connecting the catalytic domain and putative membrane-spanning
domain. Therefore, the reactivity of these MAbs with this region
probably prevents the delivery of a portion of AC toxin to the inside
of target cells. Another MAb, 6E1, recognizes the repeat region and
reduces hemolytic activity but has no effect on AC toxin-induced cAMP
accumulation. These data suggest that the epitope of 6E1 in the repeat
region of AC toxin is involved in one of the steps hypothesized to be
necessary for lysis of sheep erythrocytes, such as the formation of an
oligomeric structure, but is less important for delivery of the
catalytic domain to the target cell interior. In contrast, MAb 2A12,
which recognize amino acids 399 to 623 or 781 to 828, may
interfere with the insertion of AC toxin into the cell membrane,
resulting in partial reduction of both activities of AC toxin. The
remaining MAbs do not interfere with toxin or hemolytic activity,
suggesting either that the interaction between MAb and AC toxin does
not disrupt the conformational changes of AC toxin required for these
activities or that the affinity of these MAbs for the toxin may be too
low for them to remain bound to AC toxin when it interacts with the
target cell membrane.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 5.
Proposed epitope map of MAbs against AC toxin. The
linear sequence of AC toxin is shown along with its four major domains.
Solid bars indicate the proposed epitope of each MAb.
|
|
The mapping data described in this study suggest that the repeat region
may be immunodominant, since 6 of 12 MAbs recognize it. There seem to
be two classes of MAbs that recognize the repeat region. Two of six
MAbs, 9D4 and 2F5, clearly react with the repetitive motif located
throughout the repeat region, since they bound to all the peptides of
the repeat region constructed in this study. In parallel with these
results, MAb 9D4 recognizes other RTX toxins (11, 36) and
MAb 2F5, which was also demonstrated to react with E. coli
hemolysin in this study, would be expected to react with other RTX
toxins. The other MAbs, which recognize the repeat region, appear to
have unique epitopes or nonconforming repetitive motifs in small
portions of the repeat region.
AC toxin is a bifunctional protein exhibiting intoxication and
hemolysis. MAbs characterized in this study aid in understanding the
mechanism of each function by functional dissociation of AC toxin.
Future studies will include the use of MAbs to visualize the assembly
of AC toxin on the membrane by electron microscopy and to study the
initial interaction of this toxin with target cells under various
experimental conditions.
 |
ACKNOWLEDGMENTS |
We thank W. Sutherland for MAb production.
This work was supported by National Institutes of Health grant AI18000
(to E.L.H.), grant P30CA44579 to the University of Virginia Cancer
Center, and grant 310/98/0432 from the Grant Academy of the Czech
Republic (to P.S.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Box 419, School
of Medicine, University of Virginia, Charlottesville, VA 22908. Phone: (804) 924-5945. Fax: (804) 982-3830. E-mail:
eh2v{at}virginia.edu.
Present address: Department of Protein Chemistry, Immunnex
Corp., Seattle, WA 98101.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Arciniega, J. L.,
E. L. Hewlett,
F. D. Johnson,
A. Deforest,
S. G. F. Wassilak,
I. M. Onorato,
C. R. Manclark, and D. L. Burns.
1991.
Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis.
J. Infect. Dis.
163:135-142[Medline].
|
| 2.
|
Baumann, U.,
S. Wu,
K. M. Flaherty, and D. B. McKay.
1993.
Three-dimensional structure of the alkaline protease of Pseudomonas aeruginosa: a two-domain protein with a calcium binding parallel beta roll motif.
EMBO J.
12:3357-3364[Medline].
|
| 3.
|
Benz, R.,
E. Maier,
D. Ladant,
A. Ullmann, and P. Sebo.
1994.
Adenylate cyclase toxin (CyaA) of Bordetella pertussis.
J. Biol. Chem.
269:27231-27239[Abstract/Free Full Text].
|
| 4.
|
Berkowitz, S. A.,
A. R. Goldhammer,
E. L. Hewlett, and J. Wolff.
1980.
Activation of prokaryotic adenylate cyclase by calmodulin.
Ann. N. Y. Acad. Sci.
1:356-360.
|
| 5.
|
Betsou, F.,
P. Sebo, and N. Guiso.
1993.
CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin.
Infect. Immun.
61:3583-3589[Abstract/Free Full Text].
|
| 6.
|
Betsou, F.,
P. Sebo, and N. Guiso.
1995.
The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin.
Infect. Immun.
63:3309-3315[Abstract].
|
| 7.
|
Brooker, G.,
J. F. Harper,
W. L. Terasaki, and R. D. Moylan.
1979.
Radioimmunoassay of cyclic AMP and cyclic GMP.
Adv. Cyclic Nucleotide Res.
10:1-33[Medline].
|
| 8.
|
Chapman, M. D.,
W. M. Sutherland, and T. A. E. Platts-Mills.
1984.
Recognition of two dermatophagoides pteronyssnus-specific epitopes on antigen P1 by using monoclonal antibodies: binding to each epitope can be inhibited by serum from dust mite-allergic patients.
J. Immunol.
133:2488-2495[Abstract].
|
| 9.
|
Confer, D. L., and J. W. Eaton.
1982.
Phagocyte impotence caused by an invasive bacterial adenylate cyclase.
Science
217:948-950[Abstract/Free Full Text].
|
| 10.
|
Coote, J. G.
1992.
Structural and functional relationships among the RTX toxin determinants of gram-negative bacteria.
FEMS Microbiol. Rev.
88:137-162.
|
| 11.
|
Ehrmann, I. E.,
M. C. Gray,
V. M. Gordon,
L. S. Gray, and E. L. Hewlett.
1991.
Hemolytic activity of adenylate cyclase toxin from Bordetella pertussis.
FEBS Lett.
278:79-83[Medline].
|
| 12.
|
Farfel, Z.,
S. Konen,
E. Wiertz,
R. Klapmuts,
P. A. Addy, and E. Hanski.
1990.
Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination.
J. Med. Microbiol.
32:173-177[Abstract].
|
| 13.
|
Glaser, P.,
D. Ladant,
O. Sezer,
F. Pichot,
A. Ullmann, and A. Danchin.
1988.
The calmodulin-sensitive adenylate cyclase of Bordetella pertussis: cloning and expression in Escherichia coli.
Mol. Microbiol.
2:19-30[Medline].
|
| 14.
|
Glaser, P.,
H. Sakamoto,
J. Bellalou,
A. Ullmann, and A. Danchin.
1988.
Secretion of cyclolysin, the calmodulin-sensitive adenylate cyclase-haemolysin bifunctional protein of Bordetella pertussis.
EMBO J.
7:3997-4004[Medline].
|
| 15.
|
Gordon, V. M.,
W. W. Young,
S. M. Lechler,
M. C. Gray,
S. H. Leppla, and E. L. Hewlett.
1989.
Adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Different processes for interaction with and entry into target cells.
J. Biol. Chem.
264:14792-14796[Abstract/Free Full Text].
|
| 16.
|
Gray, M.,
G. Szabo,
A. S. Otero,
L. Gray, and E. Hewlett.
1998.
Distinct mechanisms for K+ efflux, intoxication, and hemolysis by Bordetella pertussis AC toxin.
J. Biol. Chem.
273:18260-18267[Abstract/Free Full Text].
|
| 17.
|
Guiso, N.,
M. Rocancourt,
S. Szatanih, and J. Alonso.
1989.
Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen.
Microb. Pathog.
7:373-380[Medline].
|
| 18.
|
Guiso, N.,
M. Szatanik, and M. Rocancourt.
1990.
Bordetella pertussis adenylate cyclase: a protective antigen against lethality and bacterial colonization in murine respiratory and intracerebral models, p. 207-211.
In
C. Manclark (ed.), Proceedings of the Sixth International Symposium on Pertussis. Department of Health and Human Services, Bethesda, Md.
|
| 19.
|
Guiso, N.,
M. Szatanik, and M. Rocancourt.
1991.
Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization.
Microb. Pathog.
11:423-431[Medline].
|
| 20.
|
Hackett, M.,
L. Guo,
J. Shabanowitz,
D. F. Hunt, and E. L. Hewlett.
1994.
Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis.
Science
266:433-435[Abstract/Free Full Text].
|
| 21.
|
Hackett, M.,
C. B. Walker,
L. Guo,
M. C. Gray,
S. Van Cuyk,
A. Ullmann,
J. Shabanowitz,
D. F. Hunt,
E. L. Hewlett, and P. Sebo.
1995.
Hemolytic, but not cell-invasive, activity of adenylate cyclase toxin is selectively affected by differential fatty-acylation in Escherichia coli.
J. Biol. Chem.
270:20250-20253[Abstract/Free Full Text].
|
| 22.
|
Hanski, E., and Z. Farfel.
1985.
Bordetella pertussis invasive adenylate cyclase. Partial resolution and properties of its cellular penetration.
J. Biol. Chem.
290:5526-5532.
|
| 23.
|
Hewlett, E. L., and J. D. Cherry.
1997.
New and improved vaccines against pertussis, p. 387-416.
In
M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
|
| 24.
|
Hewlett, E. L.,
I. E. Ehrmann,
N. J. Maloney,
P. R. Fremgen,
E. M. Barry,
A. A. Weiss, and M. C. Gray.
1992.
Adenylate cyclase toxin from Bordetella pertussis: characterization of toxin-catalyzed intoxication and hemolysis, p. 241-248.
In
B. Witholt, J. E. Alouf, G. J. Boulnois, P. Cossart, B. W. Dijkstra, P. Falmagne, F. J. Fehrenbach, J. Freer, H. Niemann, R. Rappuoli, et al. (ed.), Bacterial protein toxins. Gustav Fischer Verlag, Stuttgart, Germany.
|
| 25.
|
Hewlett, E. L., and V. M. Gordon.
1988.
Adenylate cyclase toxin of Bordetella pertussis, p. 193-209.
In
A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and immunity in pertussis. John Wiley & Sons, Inc., New York, N.Y.
|
| 26.
|
Hewlett, E. L.,
V. M. Gordon,
J. D. McCaffery,
W. M. Sutherland, and M. C. Gray.
1989.
Adenylate cyclase toxin from Bordetella pertussis. Identification and purification of the holotoxin molecule.
J. Biol. Chem.
264:19379-19384[Abstract/Free Full Text].
|
| 27.
|
Hewlett, E. L.,
L. Gray,
M. Allietta,
I. Ehrmann,
V. M. Gordon, and M. C. Gray.
1991.
Adenylate cyclase toxin from Bordetella pertussis. Conformational change associated with toxin activity.
J. Biol. Chem.
266:17503-17508[Abstract/Free Full Text].
|
| 28.
|
Iwaki, M.,
A. Ullmann, and P. Sebo.
1995.
Identification by in vitro complementation of regions required for cell-invasive activity of Bordetella pertussis adenylate cyclase toxin.
Mol. Microbiol.
17:1015-1024[Medline].
|
| 29.
|
Khelef, N., and N. Guiso.
1995.
Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin.
FEMS Microbiol Lett.
134:27-32[Medline].
|
| 29a.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 30.
|
Pearson, R. D.,
P. Symes,
M. Conboy,
A. A. Weiss, and E. L. Hewlett.
1987.
Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin.
J. Immunol.
139:2749-2754[Abstract].
|
| 31.
|
Rogel, A.,
Z. Farfel,
S. Goldschmidt,
J. Shiloach, and E. Hanski.
1988.
Bordetella pertussis adenylate cyclase. Identification of multiple forms of the enzyme by antibodies.
J. Biol. Chem.
263:13310-13316[Abstract/Free Full Text].
|
| 32.
|
Rogel, A.,
R. Meller, and E. Hanski.
1991.
Adenylate cyclase toxin from Bordetella pertussis. The relationship between induction of cAMP and hemolysis.
J. Biol. Chem.
266:3154-3161[Abstract/Free Full Text].
|
| 33.
|
Rose, T.,
P. Sebo,
J. Bellalou, and D. Ladant.
1995.
Interaction of calcium with Bordetella pertussis adenylate cyclase toxin.
J. Biol. Chem.
270:26370-26376[Abstract/Free Full Text].
|
| 34.
|
Sebo, P., and D. Ladant.
1993.
Repeat sequences in the Bordetella pertussis adenylate cyclase toxin can be recognized as alternative carboxy-proximal secretion signals by the Escherichia coli alpha-haemolysin translocator.
Mol. Microbiol.
9:999-1009[Medline].
|
| 35.
|
Szabo, G.,
M. C. Gray, and E. L. Hewlett.
1994.
Adenylate cyclase toxin from Bordetella pertussis produces ion conductance across artificial lipid bilayers in a calcium- and polarity-dependent manner.
J. Biol. Chem.
269:22496-22499[Abstract/Free Full Text].
|
| 36.
|
Thompson, S. A.,
L. L. Wang,
A. West, and P. F. Sparling.
1993.
Neisseria meningitidis produces iron-regulated proteins related to the RTX family of exoproteins.
J. Bacteriol.
175:811-818[Abstract/Free Full Text].
|
| 37.
|
Weiss, A. A., and E. L. Hewlett.
1986.
Virulence factors of Bordetella pertussis.
Annu. Rev. Microbiol.
40:661-686[Medline].
|
| 38.
|
Weiss, A. A.,
E. L. Hewlett,
G. A. Myers, and S. Falkow.
1983.
Tn5-induced mutations affecting virulence factors of Bordetella pertussis.
Infect. Immun.
42:33-41[Abstract/Free Full Text].
|
| 38a.
| Welch, R. Personal communication.
|
| 39.
|
Welch, R.
1991.
Pore-forming cytolysins of gram-negative bacteria.
Mol. Microbiol.
5:521-528[Medline].
|
Infection and Immunity, May 1999, p. 2090-2095, Vol. 67, No. 5
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Buboltz, A. M., Nicholson, T. L., Parette, M. R., Hester, S. E., Parkhill, J., Harvill, E. T.
(2008). Replacement of Adenylate Cyclase Toxin in a Lineage of Bordetella bronchiseptica. J. Bacteriol.
190: 5502-5511
[Abstract]
[Full Text]
-
Gunton, J. E., Gilmour, M. W., Baptista, K. P., Lawley, T. D., Taylor, D. E.
(2007). Interaction between the co-inherited TraG coupling protein and the TraJ membrane-associated protein of the H-plasmid conjugative DNA transfer system resembles chromosomal DNA translocases. Microbiology
153: 428-441
[Abstract]
[Full Text]
-
Watanabe, M., Connelly, B., Weiss, A. A.
(2006). Characterization of serological responses to pertussis.. CVI
13: 341-348
[Abstract]
[Full Text]
-
Kanack, K. J., Crawford, J. A., Tatsuno, I., Karmali, M. A., Kaper, J. B.
(2005). SepZ/EspZ Is Secreted and Translocated into HeLa Cells by the Enteropathogenic Escherichia coli Type III Secretion System. Infect. Immun.
73: 4327-4337
[Abstract]
[Full Text]
-
Schaeffer, L. M., McCormack, F. X., Wu, H., Weiss, A. A.
(2004). Bordetella pertussis Lipopolysaccharide Resists the Bactericidal Effects of Pulmonary Surfactant Protein A. J. Immunol.
173: 1959-1965
[Abstract]
[Full Text]
-
Gray, M. C., Lee, S.-J., Gray, L. S., Zaretzky, F. R., Otero, A. S., Szabo, G., Hewlett, E. L.
(2001). Translocation-Specific Conformation of Adenylate Cyclase Toxin from Bordetella pertussis Inhibits Toxin-Mediated Hemolysis. J. Bacteriol.
183: 5904-5910
[Abstract]
[Full Text]
-
Kalmusova, J.
(2001). Neisseria meningitidis RTX Protein FrpC Induces High Levels of Serum Antibodies during Invasive Disease: Polymorphism of frpC Alleles and Purification of Recombinant FrpC. Infect. Immun.
69: 5509-5519
[Abstract]
[Full Text]
-
Ramirez-Arcos, S., Szeto, J., Beveridge, T. J., Victor, C., Francis, F., Dillon, J.-A. R.
(2001). Deletion of the cell-division inhibitor MinC results in lysis of Neisseria gonorrhoeae. Microbiology
147: 225-237
[Abstract]
[Full Text]
-
Weingart, C. L., Mobberley-Schuman, P. S., Hewlett, E. L., Gray, M. C., Weiss, A. A.
(2000). Neutralizing Antibodies to Adenylate Cyclase Toxin Promote Phagocytosis of Bordetella pertussis by Human Neutrophils. Infect. Immun.
68: 7152-7155
[Abstract]
[Full Text]
-
Weingart, C. L., Weiss, A. A.
(2000). Bordetella pertussis Virulence Factors Affect Phagocytosis by Human Neutrophils. Infect. Immun.
68: 1735-1739
[Abstract]
[Full Text]
-
Gray, M. C., Ross, W., Kim, K., Hewlett, E. L.
(1999). Characterization of Binding of Adenylate Cyclase Toxin to Target Cells by Flow Cytometry. Infect. Immun.
67: 4393-4399
[Abstract]
[Full Text]